ClinicalTrials.gg
Sign In
CompletedNCT06758960Updated Mar 31, 2026

Analysis of Biological Progression and Regression of HELLP Syndrome in Time

An observational study in HELLP Syndrome and Preeclampsia, sponsored by CHU Mohammed VI Marrakech. Completed at 1 site in Morocco. Open to female participants. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by CHU Mohammed VI Marrakech · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
72
Sex
Female
01

Study summary

Prospective observational study about progression and regression of biological parameters of HELLP syndrome

Read the detailed description

Data collection included a comprehensive review of pathological histories, identification of complications based on clinical presentation, daily monitoring of biological parameters, documentation of transfusion events, recording of corticosteroid administration according to gestational age, and detailed reporting of extraction and analgesia techniques.

02

Conditions studied

  • HELLP Syndrome
  • Preeclampsia

Keywords

  • Preeclampsia
  • HELLP syndrome
  • Thrombocytopenia
  • Maternal mortality
03

In context

HELLP Syndrome

35 studies on the registry are indexed under HELLP Syndrome; 10 are open to participants now.

This study's enrollment of 72 is below the median of 188 across 20 observational studies indexed under HELLP Syndrome.

Browse HELLP Syndrome studies →

Lead sponsor

CHU Mohammed VI Marrakech is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant patients admitted to the maternal ICU from the Obstetrics Emergency department of marrakesh

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women who are admitted to the maternal ICU for a biological HELLP syndrome

Exclusion criteria

Exclusion Criteria:

  • Patients whose biological presentation was attributable to other conditions, such as microangiopathies or leukemia.
  • Patients who benefited from plasma exchange therapy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
72 participants (actual)
Target follow-up
14 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Platelets count

    Platelets count will be monitored daily before and after delivery

    Time frame: Up to 10 days

Secondary outcomes

  1. Concentration of Lactate dehydrogenase

    Monitored daily before and after delivery

    Time frame: Up to 10 days

  2. Concentration of Liver enzymes

    daily monitoring of alkaline phosphatase, alanine transaminase before and after delivery

    Time frame: Up to 10 days

07

Study locations

1 site
  • CHU Mohammed VI of Marrakech
    Marrakesh, Marrakesh-Safi 40000, Morocco
08

References and documents

Publications

  • Martin JN Jr, Blake PG, Lowry SL, Perry KG Jr, Files JC, Morrison JC. Pregnancy complicated by preeclampsia-eclampsia with the syndrome of hemolysis, elevated liver enzymes, and low platelet count: how rapid is postpartum recovery? Obstet Gynecol. 1990 Nov;76(5 Pt 1):737-41. doi: 10.1097/00006250-199011000-00001. PubMed 2216215 ↗
  • Martin JN Jr, Blake PG, Perry KG Jr, McCaul JF, Hess LW, Martin RW. The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol. 1991 Jun;164(6 Pt 1):1500-9; discussion 1509-13. doi: 10.1016/0002-9378(91)91429-z. PubMed 2048596 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All data collected throughout the trial will be shared

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Beginning 3 months and ending 1 year after the publication of results

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06758960
Lead sponsor
CHU Mohammed VI Marrakech
Responsible party
Meryem Essafti (Assistant Professor, CHU Mohammed VI Marrakech) — Principal investigator
First posted
Jan 6, 2025
Start date
Jul 1, 2023
Primary completion
Jul 31, 2025
Completion
Aug 31, 2025
Last update
Mar 31, 2026

Study contacts

Meryem Essafti, Assistant Professor
study director · CHU Mohammed VI Marrakech

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

HELLP Syndrome →

Other studies from this sponsor

CHU Mohammed VI Marrakech

Start the discussion